MedinetMEDINET Co., Ltd.2370東証グロースサービス業FY ending Sep 2025, non-consolidated, J-GAAP
About 100% of Medinet's sales come from Contracted Cell Manufacturing Business, with Cellular and tissue-based product business making up much of the rest.
It lost about ¥215 for every ¥100 of sales at the operating level.
Revenue changed +4.4% from the prior year.
FY ending Sep 2022 → FY ending Sep 2023
FY ending Sep 2022 → FY ending Sep 2023
For every ¥100 Medinet sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
Revenue by business segment, and the profit each one keeps.
※ Segment figures include inter-segment sales and do not sum to the company total
EDINET (FSA Japan)
有価証券報告書-第30期(2024/10/01-2025/09/30)
EDINET (FSA Japan)
有価証券報告書-第29期(2023/10/01-2024/09/30)
EDINET (FSA Japan)
有価証券報告書-第28期(2022/10/01-2023/09/30)
EDINET (FSA Japan)
有価証券報告書-第27期(令和3年10月1日-令和4年9月30日)
EDINET (FSA Japan)
有価証券報告書-第26期(令和2年10月1日-令和3年9月30日)
EDINET (FSA Japan)
有価証券報告書-第25期(令和1年10月1日-令和2年9月30日)
Extracted from XBRL: 43 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.